EMAIL THIS PAGE TO A FRIEND

Oncotarget

Activating transcription factor 5 enhances radioresistance and malignancy in cancer cells.


PMID 25682872

Abstract

Radiotherapy is effective for treating various types of tumors. However, some cancer cells survive after irradiation and repopulate tumors with highly malignant phenotypes that correlate with poor prognosis. It is not known how cancer cells survive and generate malignant tumors after irradiation. Here, we show that activating transcription factor 5 (ATF5) promotes radioresistance and malignancy in cancer cells after irradiation. In the G1-S phase of the cell cycle, cancer cells express high levels of ATF5, which promotes cell cycle progression and thereby increases radioresistance. Furthermore, ATF5 increases malignant phenotypes, such as cell growth and invasiveness, in cancer cells in vitro and in vivo. We have identified a new mechanism for the regeneration of highly malignant tumors after irradiation and shown that ATF5 plays a key role in the process.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

37095
Staurosporine, VETRANAL, analytical standard
C28H26N4O3